Burkitt Lymphoma (Epstein-Barr Virus - HHV-4)

For the why behind the fact

Use this page to connect what you are memorizing.

Start with the overview when a class slide, Anki card, or qbank explanation feels too thin. Then use presentation and workup to recognize the condition, and differentials to separate look-alikes.

Overview


Plain-Language Overview

Burkitt lymphoma is a very fast-growing cancer of mature B lymphocytes. Jaw or facial tumors are classic in endemic African disease; abdominal masses are common in sporadic cases. EBV is associated with many endemic cases, but not every Burkitt lymphoma is EBV-positive, and most people infected with EBV never develop this cancer. Rapid assessment and specialist treatment are important; many patients can be cured.

Clinical Definition

Burkitt lymphoma is an aggressive mature germinal-center B-cell neoplasm driven by MYC dysregulation, usually t(8;14), IGH::MYC. Monomorphic medium-sized cells, CD20/CD10/BCL6 positivity, usually absent or weak BCL2, TdT negativity and a Ki-67 index near 100% support diagnosis. Tingible-body macrophages create a starry-sky pattern, which is not specific by itself. WHO distinguishes EBV-positive and EBV-negative disease; endemic, sporadic and immunodeficiency-associated patterns remain useful clinical contexts.

Inciting Event

  • In EBV-positive disease, latent viral infection cooperates with acquired oncogenic changes and host factors; primary infection or reactivation does not inevitably initiate lymphoma.

  • Chromosomal translocation involving MYC gene activation is the critical genetic event.

  • Co-infection with Plasmodium falciparum malaria in endemic areas facilitates EBV-driven B-cell proliferation.

Latency Period

  • There is no fixed EBV-to-lymphoma incubation interval. EBV persists lifelong in many healthy people; tumor development requires additional events.

  • Once clinically apparent, tumor masses can enlarge over days to weeks; duration of symptoms does not date the original malignant transformation.

  • Immune dysfunction changes risk, but a predictable shorter latency in every immunocompromised patient is not established.

Diagnostic Delay

  • Initial symptoms often mimic common infections, leading to misdiagnosis as bacterial or viral lymphadenitis.

  • Rapid tumor growth can be mistaken for acute infections or other malignancies delaying biopsy.

  • Lack of awareness of Burkitt lymphoma in non-endemic areas contributes to delayed diagnosis.

  • Limited access to advanced diagnostic tools such as immunophenotyping and cytogenetics can postpone confirmation.

Clinical Presentation


Signs & Symptoms

  • Rapidly growing painless mass in jaw, abdomen, or other extranodal sites.

  • B symptoms including fever, night sweats, and weight loss.

  • Abdominal pain or distension due to bowel involvement.

  • Signs of tumor lysis syndrome such as nausea, vomiting, and confusion.

  • Neurological symptoms if there is CNS involvement.

History of Present Illness

  • Patients typically present with rapidly enlarging, painless lymphadenopathy or extranodal masses.

  • Common sites include the jaw (endemic form), abdomen, and ileocecal region (sporadic form).

  • Symptoms progress quickly over days to weeks, often with B symptoms such as fever, night sweats, and weight loss.

  • Abdominal involvement may cause pain, distension, or bowel obstruction.

  • Central nervous system involvement can present with neurologic deficits in advanced cases.

Past Medical History

  • Past EBV infection is common and often unrecognized. A history of mononucleosis is neither necessary nor sufficient to establish tumor EBV association.

  • Immunodeficiency conditions such as HIV/AIDS or post-transplant immunosuppression increase risk.

  • Previous episodes of malaria in endemic regions are relevant.

  • No specific prior malignancies are typically associated but immunosuppression is a key modifier.

Family History

  • No strong familial inheritance pattern is established for Burkitt lymphoma.

  • Rare familial cases may be linked to inherited immune deficiencies affecting EBV control.

  • Family history of other lymphoproliferative disorders may be noted but is not common.

Physical Exam Findings

  • Presence of a rapidly enlarging, painless mass in the jaw or facial bones in endemic Burkitt lymphoma.

  • Abdominal distension or palpable mass due to involvement of the ileocecal region in sporadic Burkitt lymphoma.

  • Lymphadenopathy in cervical, axillary, or inguinal regions.

  • Hepatosplenomegaly may be present due to systemic involvement.

  • Signs of tumor lysis syndrome such as dehydration or altered mental status in advanced cases.

Diagnostic Workup


Diagnostic Criteria

Obtain adequate tissue for integrated morphology, immunophenotyping and genetics. Typical findings include monomorphic medium-sized mature B cells, CD20/CD10/BCL6, TdT negativity, usually absent/weak BCL2 and very high Ki-67. Demonstrate an immunoglobulin-associated MYC rearrangement, commonly t(8;14), in the appropriate context. MYC rearrangement or starry-sky histology alone is not specific; exclude other high-grade B-cell lymphomas. EBER in-situ hybridization in tumor tissue, rather than past-infection serology alone, assesses EBV association.

Pathophysiology


Key Mechanisms

  • An acquired immunoglobulin enhancer juxtaposition, usually IGH on chromosome 14 with MYC on chromosome 8, increases MYC transcription. MYC is a transcription factor driving growth/metabolism; this is not an inherited germline translocation in most patients.

  • Epstein-Barr virus (EBV) infection promotes B-cell transformation and contributes to oncogenesis by latent viral gene expression.

  • Dysregulation of cell cycle control and apoptosis pathways results in rapid tumor growth.

  • High proliferation rate is reflected by a nearly 100% Ki-67 index in tumor cells.

  • The tumor microenvironment supports aggressive lymphoma expansion through immune evasion mechanisms.

InvolvementDetails
Organs

Lymph nodes are commonly enlarged due to infiltration by malignant B cells in Burkitt lymphoma.

Jaw and facial bones are frequently involved in endemic Burkitt lymphoma, causing characteristic tumor masses.

Central nervous system involvement can occur, necessitating prophylactic treatment to prevent neurological complications.

Tissues

Lymphoid tissue is the primary site of Burkitt lymphoma involvement, with rapid expansion of malignant B cells disrupting normal architecture.

Cells

The malignant cells are mature germinal-center B cells, unlike the immature TdT-positive blasts of most lymphoblastic neoplasms.

T cells provide immune surveillance but are ineffective in controlling the aggressive B cell proliferation in this lymphoma.

Chemical Mediators

c-MYC oncogene overexpression drives uncontrolled proliferation of malignant B cells in Burkitt lymphoma.

Epstein-Barr virus (EBV) latent infection contributes to oncogenesis by promoting B cell transformation and survival.

Treatments


Pharmacological Treatments

  • Cyclophosphamide

    • Mechanism:
      • Alkylates DNA leading to cross-linking and apoptosis of rapidly dividing B cells.

    • Side effects:
      • Myelosuppression

      • Hemorrhagic cystitis

      • Nausea and vomiting

    • Clinical role:
      • Component of combination regimens, not stand-alone treatment; dose and schedule are protocol/risk dependent.

  • Doxorubicin

    • Mechanism:
      • Intercalates DNA and inhibits topoisomerase II causing DNA strand breaks in lymphoma cells.

    • Side effects:
      • Cardiotoxicity

      • Myelosuppression

      • Alopecia

    • Clinical role:
      • Anthracycline component of selected combination regimens; assess cardiac function and cumulative exposure.

  • Vincristine

    • Mechanism:
      • Binds tubulin and inhibits microtubule formation, arresting mitosis in malignant B cells.

    • Side effects:
      • Peripheral neuropathy

      • Autonomic neuropathy with constipation or paralytic ileus.

      • SIADH/hyponatremia; comparatively little marrow suppression at usual doses, unlike many other cytotoxic agents.

    • Clinical role:
      • Combination-regimen component administered intravenously only; intrathecal administration can be fatal.

  • Methotrexate

    • Mechanism:
      • Inhibits dihydrofolate reductase, blocking DNA synthesis in rapidly proliferating lymphoma cells.

    • Side effects:
      • Mucositis

      • Myelosuppression

      • Hepatotoxicity

    • Clinical role:
      • Systemic high-dose and/or intrathecal component in selected protocols. High-dose systemic therapy requires hydration, urine alkalinization, leucovorin rescue and drug/renal monitoring.

  • Rituximab

    • Mechanism:
      • Monoclonal antibody targeting CD20 on B cells, inducing cell lysis and apoptosis.

    • Side effects:
      • Infusion reactions

      • Infections and hepatitis B reactivation; screen with HBsAg and anti-HBc before treatment and arrange prevention/monitoring when indicated.

      • Hypotension

    • Clinical role:
      • An important anti-CD20 component of many modern first-line combination regimens, not merely nonspecific supportive therapy; selection follows age, risk and protocol.

Non-pharmacological Treatments

  • Begin monitored IV hydration and close urine-output/electrolyte/renal surveillance for tumor lysis risk. Pharmacologic prevention uses allopurinol or rasburicase according to risk; TLS may occur before chemotherapy.

  • Supportive care includes nutrition, transfusions and infection prevention. Definitive therapy is urgent risk-adapted multidrug chemotherapy, commonly with rituximab; surgery usually obtains tissue or manages complications rather than replacing systemic treatment.

  • CNS-directed therapy is pharmacologic, with protocol-selected intrathecal methotrexate/cytarabine and/or systemic CNS-penetrating agents. It requires specialized administration; vincristine must never be given intrathecally.

Prevention


Pharmacological Prevention

  • No established pharmacological prophylaxis for Burkitt lymphoma.

  • Effective antiretroviral therapy is essential in HIV and reduces several HIV-related lymphoma risks; it does not eliminate Burkitt risk or substitute for lymphoma treatment.

  • Use antimalarial prevention for established malaria indications; a specific antimalarial regimen is not standard Burkitt lymphoma chemoprevention.

  • No approved EBV vaccine or routine antiviral strategy is established to prevent Burkitt lymphoma; latent tumor-associated infection is not treated like an ordinary acute viral illness.

  • Chemoprevention strategies are not standard for Burkitt lymphoma.

Non-pharmacological Prevention

  • Vector control and insecticide-treated nets prevent malaria and address an endemic cofactor; they should not be presented as guaranteeing lymphoma prevention.

  • Prompt evaluation of rapidly growing masses enables early diagnosis; routine population screening for Burkitt lymphoma is not established.

  • Manage HIV and immunosuppressive treatment with the responsible specialist; patients should not stop necessary immunosuppression solely to avoid lymphoma.

  • General measures that reduce saliva exposure may reduce EBV spread, but a proven public-health program specifically preventing Burkitt lymphoma is not established.

  • Nutrition and general health support treatment and recovery; they are not established specific primary prevention for Burkitt lymphoma.

Outcome & Complications


Complications

  • Tumor lysis syndrome causing acute kidney injury and electrolyte abnormalities.

  • CNS involvement leading to neurological deficits and increased morbidity.

  • Airway obstruction from large cervical or facial masses.

  • Bone marrow failure resulting in cytopenias.

  • Chemotherapy-related toxicities including infections and organ damage.

Short-term Sequelae Long-term Sequelae
  • Rapid tumor growth causing local compression symptoms such as airway compromise or bowel obstruction.

  • Tumor lysis can cause acute kidney injury spontaneously or after treatment because of the high tumor burden and rapid cell turnover.

  • Febrile neutropenia secondary to chemotherapy-induced immunosuppression.

  • TLS typically causes hyperuricemia, hyperkalemia, hyperphosphatemia and secondary hypocalcemia; arrhythmias, seizures and kidney injury may follow.

  • Mucositis and gastrointestinal symptoms from chemotherapy.

  • Second cancers are possible late effects of cytotoxic therapy; radiation is not routinely required in modern Burkitt regimens.

  • Immune recovery varies; prolonged B-cell depletion/hypogammaglobulinemia or underlying HIV can increase infection risk, but permanent generalized immunosuppression is not inevitable.

  • Neurocognitive deficits if CNS involvement or neurotoxic chemotherapy occurred.

  • Fertility impairment from alkylating agents or radiation.

  • Cardiomyopathy related to anthracycline chemotherapy.

Differential Diagnoses


Burkitt Lymphoma (Epstein-Barr Virus - HHV-4) versus Diffuse Large B-Cell Lymphoma (DLBCL)

Burkitt Lymphoma (Epstein-Barr Virus - HHV-4)

Diffuse Large B-Cell Lymphoma (DLBCL)

Commonly affects children and young adults

Typically affects older adults, median age >60 years

Medium-sized B cells with a starry sky pattern due to macrophages

Large, pleomorphic B cells with diffuse growth pattern

Usually IG::MYC, most often t(8;14), with typical morphology and phenotype.

MYC rearrangements can occur in DLBCL/high-grade B-cell lymphomas, including with BCL2; the rearrangement alone does not distinguish Burkitt.

EBV-positive and EBV-negative forms occur; endemic cases are much more often EBV-associated.

Often EBV-negative, but EBV-positive DLBCL is a recognized entity and can occur without overt immunodeficiency.

Burkitt Lymphoma (Epstein-Barr Virus - HHV-4) versus Acute Lymphoblastic Leukemia (ALL)

Burkitt Lymphoma (Epstein-Barr Virus - HHV-4)

Acute Lymphoblastic Leukemia (ALL)

Extranodal masses are classic, but marrow and peripheral-blood involvement can produce a leukemic presentation.

Marrow failure, circulating blasts or extramedullary disease may occur; blood blasts need not be present at diagnosis.

Mature B cells in tissue biopsy with high proliferation index

Predominantly lymphoblasts in bone marrow and blood

TdT negative mature B cells

TdT positive immature lymphoid cells

Usually immunoglobulin-associated MYC rearrangement in a mature B-cell neoplasm.

B-ALL has diverse genetic subtypes, including ETV6::RUNX1 and BCR::ABL1; rare MYC-rearranged precursor cases require integrated classification.

Burkitt Lymphoma (Epstein-Barr Virus - HHV-4) versus Hodgkin Lymphoma

Burkitt Lymphoma (Epstein-Barr Virus - HHV-4)

Hodgkin Lymphoma

Sheets of monotonous medium-sized B cells with starry sky macrophages

Presence of Reed-Sternberg cells in a mixed inflammatory background

Jaw or abdominal mass with rapid growth

Painless lymphadenopathy often in cervical region with B symptoms

Strong association in endemic cases, but not all Burkitt is EBV-positive.

EBV association varies by age, geography and subtype; it is enriched in mixed cellularity but not restricted to it.

Usually CD20/CD10/BCL6-positive, TdT-negative mature B cells.

In classic Hodgkin lymphoma, Reed-Sternberg cells are usually CD30-positive, often CD15-positive and weakly PAX5-positive; CD20 expression can vary.

Burkitt Lymphoma (Epstein-Barr Virus - HHV-4) versus Mantle Cell Lymphoma

Burkitt Lymphoma (Epstein-Barr Virus - HHV-4)

Mantle Cell Lymphoma

t(8;14) translocation involving MYC gene

t(11;14) translocation involving CCND1 gene

Commonly affects children and young adults

Typically affects middle-aged to older adults

Extranodal masses, especially jaw or abdomen

Generalized lymphadenopathy and splenomegaly

Usually CD10/BCL6-positive and cyclin D1-negative, with a very high proliferation index.

Usually CD5/cyclin D1-positive with CCND1 rearrangement; rare cyclin D1-negative variants require additional studies.

Burkitt Lymphoma (Epstein-Barr Virus - HHV-4) versus T-Cell Lymphoblastic Lymphoma

Burkitt Lymphoma (Epstein-Barr Virus - HHV-4)

T-Cell Lymphoblastic Lymphoma

B-cell lineage with mature medium-sized cells

T-cell lineage with immature lymphoblasts

Jaw or abdominal disease is typical; mediastinal involvement is uncommon but not impossible.

Anterior mediastinal mass is common, particularly in adolescents, but not required for T-lymphoblastic lymphoma.

TdT negative, CD20 positive mature B cells

TdT positive, CD3 positive immature T cells